These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 10682928)

  • 1. Expression of BCL-2 oncoprotein on tumor cells and tumor-infiltrating lymphocytes (TIL) in meningiomas.
    Roessler K; Dietrich W; Kitz K
    Neurosurg Rev; 1999 Dec; 22(4):205-9. PubMed ID: 10682928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas.
    Karamitopoulou E; Perentes E; Tolnay M; Probst A
    Hum Pathol; 1998 Feb; 29(2):140-5. PubMed ID: 9490273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptotic activity and bcl-2 immunoreactivity in meningiomas. Association with grade and outcome.
    Abramovich CM; Prayson RA
    Am J Clin Pathol; 2000 Jul; 114(1):84-92. PubMed ID: 10884803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proliferation and DNA fragmentation in meningioma subtypes.
    Maier H; Wanschitz J; Sedivy R; Rössler K; Ofner D; Budka H
    Neuropathol Appl Neurobiol; 1997 Dec; 23(6):496-506. PubMed ID: 9460716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
    Tomsová M; Melichar B; Sedláková I; Steiner I
    Gynecol Oncol; 2008 Feb; 108(2):415-20. PubMed ID: 18037158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma.
    Du Z; Abedalthagafi M; Aizer AA; McHenry AR; Sun HH; Bray MA; Viramontes O; Machaidze R; Brastianos PK; Reardon DA; Dunn IF; Freeman GJ; Ligon KL; Carpenter AE; Alexander BM; Agar NY; Rodig SJ; Bradshaw EM; Santagata S
    Oncotarget; 2015 Mar; 6(7):4704-16. PubMed ID: 25609200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
    Abdelzaher E; El-Gendi SM; Yehya A; Gowil AG
    Br J Neurosurg; 2011 Dec; 25(6):707-13. PubMed ID: 20979437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
    Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
    APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunocytochemical analysis of glucose transporter protein-1 (GLUT-1) in typical, brain invasive, atypical and anaplastic meningioma.
    van de Nes JA; Griewank KG; Schmid KW; Grabellus F
    Neuropathology; 2015 Feb; 35(1):24-36. PubMed ID: 25168354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
    Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K
    Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcl2 and ROS1 expression in human meningiomas: an analysis with respect to histological subtype.
    Girish V; Sachdeva N; Minz RW; Radotra B; Mathuria SN; Arora SK
    Indian J Pathol Microbiol; 2005 Jul; 48(3):325-30. PubMed ID: 16761743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of COX-2 and VEGF expression in histopathologic grading and invasiveness of meningiomas.
    Lee SH; Lee YS; Hong YG; Kang CS
    APMIS; 2014 Jan; 122(1):16-24. PubMed ID: 23756256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of extracellular matrix-degrading proteins in classic, atypical, and anaplastic meningiomas.
    von Randow AJ; Schindler S; Tews DS
    Pathol Res Pract; 2006; 202(5):365-72. PubMed ID: 16563650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative proteomic profiles of meningioma subtypes.
    Okamoto H; Li J; Vortmeyer AO; Jaffe H; Lee YS; Gläsker S; Sohn TS; Zeng W; Ikejiri B; Proescholdt MA; Mayer C; Weil RJ; Oldfield EH; Zhuang Z
    Cancer Res; 2006 Oct; 66(20):10199-204. PubMed ID: 17047085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptosis is associated with atypical or malignant change in meningiomas. An in situ labelling and immunohistochemical study.
    Ng HK; Chen L
    Histopathology; 1998 Jul; 33(1):64-70. PubMed ID: 9726051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour infiltrating lymphocyte density differs by meningioma type and is associated with prognosis in atypical meningioma.
    Turner CP; McLay J; Hermans IF; Correia J; Bok A; Mehrabi N; Gock S; Highet B; Curtis MA; Dragunow M
    Pathology; 2022 Jun; 54(4):417-424. PubMed ID: 35082053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anaplastic meningioma versus meningeal hemangiopericytoma: immunohistochemical and genetic markers.
    Rajaram V; Brat DJ; Perry A
    Hum Pathol; 2004 Nov; 35(11):1413-8. PubMed ID: 15668900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical expression of Ets-1 transcription factor and the urokinase-type plasminogen activator is correlated with the malignant and invasive potential in meningiomas.
    Kitange G; Tsunoda K; Anda T; Nakamura S; Yasunaga A; Naito S; Shibata S
    Cancer; 2000 Dec; 89(11):2292-300. PubMed ID: 11147600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spatially Resolved and Quantitative Analysis of the Immunological Landscape in Human Meningiomas.
    Yeung J; Yaghoobi V; Aung TN; Vesely MD; Zhang T; Gaule P; Gunel M; Rimm DL; Chen L
    J Neuropathol Exp Neurol; 2021 Jan; 80(2):150-159. PubMed ID: 33393633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of p63 immunoreactivity with tumor grade in meningiomas.
    Rushing EJ; Olsen C; Man YG
    Int J Surg Pathol; 2008 Jan; 16(1):38-42. PubMed ID: 18203782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.